What is PROCEPT BioRobotics?
Headquartered in San Jose, California, PROCEPT BioRobotics is a commercial-stage medical technology firm specializing in image-guided robotic systems. Since its inception in 2007, the company has focused on the intersection of robotics, real-time multidimensional imaging, and personalized treatment planning. Its flagship platform provides a transformative approach to urologic surgery, enabling surgeons to perform targeted prostate tissue removal with high precision. By decoupling clinical outcomes from surgeon experience and anatomical variability, PROCEPT has established a robust market presence, currently trading on the NASDAQ under the ticker symbol PRCT. The company's commitment to minimally invasive, durable solutions positions it as a critical player in the evolving landscape of robotic-assisted surgery.
How much funding has PROCEPT BioRobotics raised?
PROCEPT BioRobotics has raised a total of $601.3M across 10 funding rounds:
Series C
$6M
Debt
$7.7M
Series A
$7.7M
Series D
$42M
Series B
$42M
Series E
$118M
Series F
$77M
Series G
$85M
Share Placement
$163.9M
Debt
$52M
Series C (2013): $6M, investors not publicly disclosed
Debt (2014): $7.7M, investors not publicly disclosed
Series A (2014): $7.7M, investors not publicly disclosed
Series D (2015): $42M featuring Novo A/S
Series B (2015): $42M backed by Novo Holdings
Series E (2018): $118M with participation from Viking Global Investors, Perceptive Advisors, and CPMG
Series F (2020): $77M, investors not publicly disclosed
Series G (2021): $85M supported by T. Rowe Price, Perceptive Advisors, CPMG, Fidelity, Duquesne Family Office, and Viking Global Investors
Share Placement (2021): $163.9M, investors not publicly disclosed
Debt (2022): $52M backed by CIBC Innovation Banking
Key Investors in PROCEPT BioRobotics
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
T. Rowe Price
T. Rowe Price is a global asset management organization providing investment solutions through active management, fundamental analysis, and long-term perspectives.
Perceptive Advisors
Founded in 1999, Perceptive Advisors is a New York-based investment firm dedicated to funding innovative healthcare and life sciences technologies.
What's next for PROCEPT BioRobotics?
The recent strategic financing provides PROCEPT BioRobotics with the necessary liquidity to scale its commercial operations and further penetrate the global urology market. As the company transitions from its development-heavy roots into a mature, publicly traded entity, the focus will likely shift toward expanding the clinical adoption of its robotic platform and investing in next-generation product iterations. By leveraging its strong balance sheet, PROCEPT is well-positioned to maintain its competitive advantage, drive long-term shareholder value, and continue its mission of setting new benchmarks for patient outcomes in prostate disease management.
See full PROCEPT BioRobotics company page
